Recently, the pyrophosphatase DCPS (Decapping scavenger enzyme) was identified and validated as a potential therapeutic target in Acute Myeloid Leukemia (AML), demonstrating that pharmacological inhibition of DCPS is detrimental for AML cells but dispensable for normal haematopoiesis [1]. Here, DCPS is linked to acute myeloid leukemia.